Post-Approval Study of the Implantable Miniature Telescope
Launched by VISIONCARE, INC. · Dec 20, 2012
Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
ECD sub-study. At investigative sites participating in the ECD Sub-Group study, corneal endothelial cell density will be measured by non-contact specular microscopy in a subgroup of 150 patients enrolled in the IMT-PAS-01 in the eye schedule for and implanted with the intraocular telescope at study entry, 3 months, 12, months, 24 months, 36 months, 48 months and 60 months.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • stable severe (BVDCA of 10/160 or poorer) to profound (BCDVA of 20/800 or better) vision impairment caused by bilateral central scotomas associated with end-stage age-related macular degeneration.
- • 65 years of age or older
- • retinal findings of geographic atrophy or disciform scar with foveal involvement
- • visually significant cataract
- • agree to undergo pre- and post-surgery training and assessment
- • achieve at least a 5-letter improvement with external telescope
- • have adequate peripheral vision in the eye not scheduled for surgery
- Exclusion Criteria:
- • Stargardt's macular dystrophy
- • Anterior chamber depth \< 3.0mm
- • Presence of corneal guttate
- • Do not meet minimum age and endothelial cell density requirements
- • evidence of CNV or treatment of CNV within the past 6 months
- • cognitive impairment that would interfere with ability to understand and complete Acceptance of Risk and Informed Decision Agreement or prevent proper training/rehabilitation
- • previous intraocular or cornea surgery of any kind in operative eye, including any type of surgery for either refractive or therapeutic purposes or who have prior or expected ophthalmic related surgery within 30 days preceding intraocular telescope surgery
- • history of steroid-responsive rise in intraocular pressure, uncontrolled glaucoma, or preoperative IOP \>22 mm Hg while on maximum medication
- • known sensitivity to post-operative medications
- • history of eye rubbing or an ocular condition that predisposes eye rubbing
- • myopia \>6.0 D
- • hyperopia \>4.0D
- • axial length \<21mm
- • narrow angle, i.e., \<Schaffer grade 2
- • cornea stromal or endothelian dystrophies, including guttate
- • inflammatory ocular disease
- • zonular weakness/instability of crystalline lens, or pseudoexfoliation
- • diabetic retinopathy
- • untreated retinal tears
- • retinal vascular disease
- • optic nerve disease
- • history of retinal detachment
- • intraocular tumor
- • retinitis pigmentosa
About Visioncare, Inc.
VisionCare, Inc. is a pioneering medical device company dedicated to advancing the field of ophthalmology through innovative solutions for vision-related disorders. Specializing in the development of cutting-edge implantable devices, VisionCare focuses on enhancing patient outcomes and quality of life by addressing unmet clinical needs in vision correction and management. With a commitment to rigorous research and clinical trials, the company aims to establish new standards of care in the treatment of eye diseases, leveraging its expertise to drive meaningful advancements in the field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Atlanta, Georgia, United States
Sarasota, Florida, United States
Mcallen, Texas, United States
Sacramento, California, United States
Chesterfield, Missouri, United States
New York, New York, United States
Phoenix, Arizona, United States
Eugene, Oregon, United States
Beverly Hills, California, United States
Chandler, Arizona, United States
Phoenix, Arizona, United States
Fullerton, California, United States
Loma Linda, California, United States
Parker, Colorado, United States
Pensacola, Florida, United States
Ann Arbor, Michigan, United States
Patients applied
Trial Officials
Oliver D Schein, MD
Principal Investigator
Johns Hopkins University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials